What can we learn from Australian Orthopaedic Association National Joint Replacement Registry 2016 annual report?

Tianlong Huang¹, Wanchun Wang¹, Daniel George², Xinzhan Mao¹, Stephen Graves³

¹Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha 410001, China; ²Department of Orthopaedics, Flinders Medical Centre, Bedford Park, South Australia, Australia; ³AOA National Joint Replacement Registry, Discipline of Public Health, School of Population Health, University of Adelaide, South Australia, Australia

Correspondence to: Wanchun Wang. Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha 410001, China. Email: wwc1962@hotmail.com.

Received: 27 December 2016; Accepted: 09 February 2017; Published: 22 April 2017. doi: 10.21037/aoj.2017.02.01 View this article at: http://dx.doi.org/10.21037/aoj.2017.02.01

The Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) publish their report every year, we have previously analyzed the 2014 annual report, which contained 410,767 hip replacements and 480,440 knee replacements (1). This year is the 15th year for AOANJRR. Therefore, they have now published 15-year data for hip and knee replacements. It is also the first year they have published shoulder replacements, which contains 32,406 shoulder procedures (2).

The aim of national registries is to decrease the revision rates of arthroplasties by detecting outlier implant performance earlier. Through 15 years of work, we can see the effect of the registry data, with the proportion of revision hip procedures reported to the registry declining from 12.9% of all hip procedures in 2003 to 9.6% in 2015. Revision knee procedures declined from a peak of 8.8% in 2004 to 7.4% in 2015. These are now the lowest proportions ever reported to the registry.

The AOANJRR annual report always presents the data and results they have collected but does not offer to explain the meaning of the data and results. They encourage surgeons to interpret the data using their own experience and understanding. We have analyzed the new data which we are most interested in and review the different results in comparison to our last editorial (1). We must emphasize that our following analysis and interpretation of the AOANJRR 2016 report are based on the authors' personal understanding and clinical experience. All the data presented is from AOANJRR 2016 annual report, which can be found on the official website. We encourage all readers to download their free copy and check the data against your own interests and experience. We are happy to discuss differences of opinion if the reader has some alternative interpretations of the data.

In this article, we continue to put our focus on hip and knee replacements because this is our area of interest and it is not very common for total or reverse shoulder replacements to be performed in Chinese hospitals. The 2016 annual report contains 498,660 hip replacements and 592,577 knee replacements, with an additional 87,983 (17.62%) hip and 112,137 (18.92%) knee replacements compared to the 2014 annual report. Compared to our last article, the cases of total hip arthoplasty (THA) or total knee arthroplasty (TKA) have increased almost 20%, furthermore, some of the data have shown different results which may change our clinical considerations. Hence, we analyze the annual report again to give some further insights to our readers.

Hip and knee replacements in younger patients

The focus of the 2016 annual report is on the outcome of hip and knee replacements in younger patients (those aged less than 55 years). In our experience, Chinese patients receiving primary THA are relatively younger than Australian patients due to the increased incidence of avascular necrosis of femoral head, developmental dysplasia of the hip (DDH) and ankylosing spondylitis. Therefore the current data is of very important references for our prostheses choice.

	1	1	2	1 1	1	0 ,	, u	, ,
Fixation	N revised	N total	1 yr	3 yrs	5 yrs	7 yrs	10 yrs	15 yrs
Cemented	69	845	1.3 (0.7, 2.4)	2.3 (1.4, 3.6)	3.5 (2.4, 5.0)	4.7 (3.3, 6.5)	8.2 (6.2, 10.8)	-
Cementless	938	24,885	1.5 (1.3, 1.7)	2.7 (2.5, 2.9)	3.5 (3.2, 3.8)	4.3 (4.0, 4.6)	5.5 (5.1, 5.9)	8.9 (7.9, 10.0)
Hybrid	203	5,226	1.2 (0.9, 1.5)	2.0 (1.6, 2.4)	2.9 (2.4, 3.4)	4.3 (3.6, 5.1)	6.3 (5.4, 7.4)	11.7 (9.2, 14.8)
Total	1,210	30,956	-	-	-	-	-	_

Table 1 Cumulative percent revision of primary total conventional hip replacement in patients aged <55 years by fixation (primary diagnosis OA)

All procedures using metal/metal prostheses with head size larger than 32 mm have been excluded.



Figure 1 Cumulative percent revision of primary total conventional hip replacement in patients aged <55 years by fixation (primary diagnosis OA).

The revision rate of hip and knee arthroplasty in younger patients is a major focus of 2016 AOANJRR annual report. It is believed that younger patients have higher rates of revision. The purpose of this analysis is to provide information on how best to optimize the outcome of these procedures in this patient population (aged less than 55 years).

In the 2016 AOANJRR annual report, there are 43,380 patients whose age was less than 55 years up to and including 31 December 2015, which constitutes about 13.1% of cases for all primary THA. Compared to the data from 2003, the total number of THA procedures has increased by 96.2%, while the percentage of cases aged under 55 increased from 11.7% to 13.1%. From these data, we can infer that the growth of THA's has not been due to broadening the operative indications.

The major indications for THA in the less than 55-year old age group are osteoarthritis (OA) (78.04%), avascular necrosis of the femoral head (8.71%) and DDH (6.41%). The revision rates over 10 and 15 years in the less than 55-year age group (with the primary diagnosis of OA) are 5.8% and 9.9%, compared to 5.1% and 8.0% revision rate for all age groups (with the same primary diagnosis of OA).

We feel that age does not have a significant impact on the revision rate. For femoral neck fractures in young patients, some surgeons choose THA as first line treatment when the fracture is comminuted and displaced where the surgeon feels that nonunion and necrosis of femoral head are highly likely. The data implies that it should not be the first line treatment as the revision rates over 3 and 10 years are 6.2% and 15.5% respectively. This implies the results of THA for femoral neck fractures is not as good as perhaps some surgeons believe and possibly could be deferred following a trial of less invasive treatments.

In this group of patients, most THA are cementless (80.4%), Hybrid and cemented THA are performed less frequently (16.9% and 2.7% respectively) (*Table 1*). The revision rate at 10 years was 5.5% for cementless, 6.3% for hybrid and 8.2% for cemented and the revision rate at 15 years was 8.9% for cementless and 11.7% for hybrid (*Table 1,Figure 1*). Interestingly, there is no difference in the revision rate with different types of fixation when non-XLPE (cross-linked polyethylene) is excluded from the analysis (*Table 2,Figure 2*). This result implies non-XLPE may be the major problem in THA, XLPE is more important than the fixation choice. Considering the situation in China, we strongly recommend all total hip replacements not to use non-XLPE bearing.

In the 2016 AOANJRR report, there are 2,579 THA in the less than 55-year age group with the primary indication being DDH. The revision rate after 10 and 15 years in this group was 5.7% and 9.9% respectively (*Table 3*, *Figure 3*), compared to 5.8% and 9.9% revision rates in the same age group with a primary indication being OA. This result implies that while the procedure is technically challenging for the surgeon, the outcomes are comparable to other that for primary OA (*Table 4*,*Figure 4*). We interpret this data as an indication for THA for all patients who have met the operative indications for THA, following maturation of the osteoepiphysis, with age not being a direct contraindication.

Annals of Joint, 2017

 Table 2 Cumulative percent revision of primary total conventional hip replacement in patients aged <55 years by fixation (primary diagnosis OA, excluding non XLPE)</th>

Fixation	N revised	N total	1 yr	3 yrs	5 yrs	7 yrs	10 yrs	15 yrs
Cemented	4	199	1.5 (0.5, 4.7)	1.5 (0.5, 4.7)	2.5 (0.9, 6.9)	-	-	-
Cementless	821	23,795	1.5 (1.4, 1.7)	2.6 (2.4, 2.9)	3.4 (3.2, 3.7)	4.2 (3.9, 4.5)	5.2 (4.8, 5.6)	7.0 (6.2, 8.0)
Hybrid	137	4,662	1.2 (1.0, 1.6)	1.9 (1.6, 2.4)	2.7 (2.2, 3.3)	3.8 (3.1, 4.6)	5.2 (4.2, 6.4)	-
Total	962	28,656	-	_	-	-	-	-

All procedures using metal/metal prostheses with head size larger than 32 mm have been excluded.





Figure 2 Cumulative percent revision of primary total conventional hip replacement in patients aged <55 years by fixation (primary diagnosis OA, excluding non XLPE).

Figure 3 Cumulative percent revision of primary total conventional hip replacement in patients aged <55 years (primary diagnosis DDH).

The set of the set of	onal hip replacement in patients aged <55 years (primary diagnosis DDH)	in patients aged	placement in	hip re	total conventional	primary to	percent revision of	Cumulative	e 3 (Tabl
--	---	------------------	--------------	--------	--------------------	------------	---------------------	------------	-------	------

Hip class	N revised	N total	1 yr	3 yrs	5 yrs	7 yrs	10 yrs	14 yrs
Total conventional	120	2,579	2.0 (1.5, 2.6)	3.0 (2.3, 3.7)	3.6 (2.9, 4.4)	4.4 (3.6, 5.4)	5.7 (4.6, 6.9)	9.9 (7.8, 12.7)
Total	120	2,579	-	-	-	-	-	-

All procedures using metal/metal prostheses with head size larger than 32 mm have been excluded.

In the 2016 AOANJRR annual report, there are 33,897 TKA patients who were less than 55 years of age up to and including 31 December 2015, which is about 7.0% of the total cases for primary TKA. Compared to the data from 2003, the total number of TKA cases has increased 130.4%, but the percentage in this age group only increased from 6.8% to 7.0%. From this data, we can again infer that the growth of overall TKA was not from broadening the surgical indications.

The major indications for TKA were OA (93.7%) and rheumatoid arthritis (3.6%) (*Table 5*). The revision rate after 10 and 15 years in the less than 55 years age group with OA as the primary diagnosis was 10.9% and 15.7%

respectively (*Table 6*). This is in comparison to 5.3% and 7.3% for 10 and 15 year revision rates in all age groups (*Table 7*). Unlike the results for THA, age appears to have a greater impact on revision rates. The long-term results of TKA in younger patients are not as promising as the results for THA, meaning greater work should be done to prevent of delay the requirement for TKA in the young age groups.

In this age group, there are four factors which will affect the revision rate. Minimally stabilized prostheses (*Table 8, Figure 5*), XLPE (*Table 9, Figure 6*), patellar resurfacing (*Table 10, Figure 7*) and computer navigation (*Table 11, Figure 8*) were associated with lower rates of revision. Other factors such as prostheses fixation,

Hip class	N revised	N total	1 yr	3 yrs	5 yrs	7 yrs	10 yrs	15 yrs
Total conventional	1,210	30,956	1.4 (1.3, 1.6)	2.5 (2.4, 2.7)	3.4 (3.2, 3.6)	4.3 (4.0, 4.6)	5.8 (5.4, 6.2)	9.9 (9.0, 11.0)
Total	1,210	30,956	_	_	_	_	_	_

Table 4 Cumulative percent revision of primary total conventional hip replacement in patients aged <55 years (primary diagnosis OA)

All procedures using metal/metal prostheses with head size larger than 32 mm have been excluded



Figure 4 Cumulative percent revision of primary total conventional hip replacement in patients aged <55 years (primary diagnosis OA).

bearing mobility, image derived instrumentation (IDI) have no difference in 10-year survivorship. Of course, prostheses choice also highly affects the revision rate. There are 17 prosthesis combinations which have 10-year revision rate data, only three of the 17 combinations have less than 10% revision rate at the 10-year follow-up. They are Nexgen CR with Nexgen, Nexgen CR Flex with Nexgen and PFC Sigma PS with MBT.

Ten- and 15-year prosthesis outcomes

This year is the 15th year for the AOANJRR. They have now published 15 years of data for hip and knee replacements and their revisions. In these reports, the

Table 5 Primary diagnosis of primary total knee replacement by age									
Drimon diagnosia	<	55	≥š	55	Total				
	Ν	Col, %	Ν	Col, %	Ν	Col, %			
Osteoarthritis	31,774	93.7	450,599	97.8	482,373	97.5			
Rheumatoid arthritis	1,228	3.6	5,846	1.3	7,074	1.4			
Other inflammatory arthritis	331	1.0	2,102	0.5	2,433	0.5			
Osteonecrosis	121	0.4	1,500	0.3	1,621	0.3			
Tumor	358	1.1	249	0.1	607	0.1			
Fracture	30	0.1	253	0.1	283	0.1			
Chondrocalcinosis	1	0	19	0	20	0			
Other	54	0.2	106	0	160	0			
Total	33,897	100.0	460,674	100.0	494,571	100.0			

Table 6 Cumulat	Table 6 Cumulative percent revision of primary total knee replacement in patients aged <55 years (primary diagnosis OA)										
Type of primary	N revised	N total	1 yr	3 yrs	5 yrs	7 yrs	10 yrs	15 yrs			
Total knee	2,300	31,774	1.7 (1.6, 1.9)	5.1 (4.8, 5.4)	7.0 (6.7, 7.3)	8.5 (8.1, 8.9)	10.9 (10.4, 11.4)	15.7 (14.2, 17.3)			
Total	2,300	31,774	-	-	-	-	_	_			

Annals of Joint, 2017

		- · · F		I				
Primary diagnosis	N revised	N total	1 yr	3 yrs	5 yrs	7 yrs	10 yrs	15 yrs
Osteoarthritis	17,213	482,373	1.0 (1.0, 1.1)	2.7 (2.7, 2.8)	3.6 (3.6, 3.7)	4.4 (4.3, 4.4)	5.3 (5.2, 5.4)	7.3 (7.1, 7.6)
Rheumatoid arthritis	246	7,074	1.0 (0.8, 1.3)	2.3 (1.9, 2.6)	2.9 (2.5, 3.3)	3.9 (3.4, 4.5)	4.8 (4.2, 5.5)	6.8 (5.4, 8.5)
Other inflammatory arthritis	102	2,433	1.5 (1.1, 2.1)	3.3 (2.6, 4.2)	4.2 (3.4, 5.2)	5.0 (4.0, 6.1)	6.4 (5.2, 8.0)	-
Osteonecrosis	74	1,621	1.1 (0.7, 1.8)	3.7 (2.8, 4.8)	4.9 (3.8, 6.3)	5.6 (4.4, 7.1)	6.4 (5.0, 8.2)	-
Other	96	1,070	2.4 (1.6, 3.7)	7.7 (6.1, 9.9)	10.4 (8.3, 13.0)	12.6 (10.1, 15.7)	16.3 (12.9, 20.6)	-
Total	17,730	494,571	_	-	-	-	-	-

Table 7 Cumulative percent revision of primary total knee replacement by primary diagnosis

Only primary diagnoses with over 1,000 procedures have been listed.

Table 8 Cumulative percent revision of primary total knee replacement in patients aged <55 years by stability (primary diagnosis OA)

Stability	N revised	N total	1 yr	3 yrs	5 yrs	7 yrs	10 yrs	15 yrs
Fully stabilised	17	242	3.1 (1.4, 6.9)	9.3 (5.4, 15.8)	-	_	-	-
Hinged	13	73	4.2 (1.4, 12.4)	15.8 (8.8, 27.6)	15.8 (8.8, 27.6)	19.2 (10.7, 33.0)	-	-
Minimally stabilised	1,630	22,817	1.5 (1.4, 1.7)	4.8 (4.5, 5.1)	6.7 (6.4, 7.1)	8.1 (7.7, 8.6)	10.5 (9.9, 11.0)	14.8 (13.5, 16.2)
Posterior stabilised	638	8,631	2.2 (1.9, 2.5)	5.6 (5.1, 6.1)	7.4 (6.8, 8.1)	9.2 (8.5, 10.0)	12.1 (11.0, 13.2)	-
Total	2,298	31,763	_	_	_	_	_	_

Excluding 11 procedures with unknown stability.



Figure 5 Cumulative percent revision of primary total knee replacement in patients aged <55 years by stability (primary diagnosis OA).

number of individual combinations of femoral and acetabular hip prostheses with 10-year outcomes has increased by 20.3%. There are 71 femoral and acetabular combinations with 10-year outcome data; these prosthesis combinations account for 62.3% of all primary THA. Checking the 10-year outcome data, we find only seven combinations with a revision rate less than 3%, they are the Alloclassic with Trilogy (1.9%), Exeter V40 with Mallory-Head (2.9%), MS 30 with Fitmore (2.5%), MS 30 with Low Profile Cup (2.4%), Natural Hip with Allofit (1.9%), Summit with Pinnacle (2.8%) and Synergy with Trident (Shell) (3.0%). In these seven prosthesis combinations, Natural Hip with Allofit and Synergy with Trident (Shell) have not had any reported use in primary THA in the 2015 annual report, this also means these two combinations have

Page 6 of 9

	r		r y y y y	· · · · · ·	I and a solution	· / · · · · / I · / · ·	,	
Polyethylene type	N revised	N total	1 yr	3 yrs	5 yrs	7 yrs	10 yrs	15 yrs
Non XLPE	1,985	22,673	1.8 (1.7, 2.0)	5.6 (5.3, 5.9)	7.6 (7.2, 8.0)	9.2 (8.7, 9.6)	11.7 (11.1, 12.2)	16.5 (15.0, 18.1)
XLPE	314	9,092	1.4 (1.1, 1.6)	3.6 (3.2, 4.1)	4.9 (4.3, 5.5)	5.6 (5.0, 6.4)	7.2 (6.1, 8.6)	_
Total	2,299	31765	_	-	_	_	_	_

Table 9 Cumulative percent revision of primary total knee replacement in patients aged <55 years by polyethylene type (primary diagnosis OA)

Excluding nine procedures with unknown bearing surface.





Figure 6 Cumulative percent revision of primary total knee replacement in patients aged <55 years by polyethylene type (primary diagnosis OA).

Figure 7 Cumulative percent revision of primary total knee replacement in patients aged <55 years by patella usage (primary diagnosis OA).

Table 10 Cumulative percent revis	sion of primary total kn	iee replacement in	patients aged <5	5 years by patella usa	ge (primary diagnosis OA)
-----------------------------------	--------------------------	--------------------	------------------	------------------------	---------------------------

Patella usage	N revised	N total	1 yr	3 yrs	5 yrs	7 yrs	10 yrs	15 yrs
Patella used	940	15,245	1.5 (1.3, 1.7)	4.3 (4.0, 4.7)	6.2 (5.7, 6.7)	7.6 (7.1, 8.1)	10.2 (9.5, 11.0)	13.7 (12.4, 15.1)
No patella	1,360	16,529	1.9 (1.7, 2.1)	5.8 (5.4, 6.2)	7.7 (7.2, 8.2)	9.3 (8.7, 9.8)	11.6 (10.9, 12.3)	16.8 (14.8, 19.1)
Total	2,300	3,1774	-	-	-	-	-	-

achieved only 10-year outcome data.

There are 46 total knee replacement combinations with 10-year outcome data, these prosthesis combinations accounts for 78.9% of all primary TKA. Checking the 10-year outcome data, we find only six combinations with revision rates less than 4%, they are the Nexgen CR with Nexgen (3.0%), Nexgen CR Flex with Nexgen (2.9%), Nexgen CR Flex with Nexgen TM CR (3.1%), PFC Sigma CR with AMK Duofix (3.2%), PFC Sigma CR with PFC Sigma (3.5%), and Triathlon CR with Triathlon (3.4%). In these six combinations, PFC Sigma CR with AMK Duofix has only outcome data for the previous 10 years.

There are 7 hips (*Table 12*) and 14 knees (*Table 13*) prosthesis combinations with 15-year outcome data, only

Secur-Fit Plus with Trident (Shell) (4.3%) in THA and Nexgen CR with Nexgen (4.5%) in TKA have less than a 5% revision rate. Interestingly, the 10-year revision rate for the combination of Secur-Fit Plus with Trident (Shell) is 3.2%, was not the best combination in the 10-year outcome data.

New prostheses choice

Some surgeons prefer short femoral stems for the patients because it is thought to preserve the proximal femur bone. These types of femoral stems are called mini stems in AOANJRR reports. There have been 2,102 procedures using mini stems undertaken for OA, which is less than 1% of all THA. The 10-year revision rate for a mini stem is 6.6%

 Table 11 Cumulative percent revision of primary total knee replacement in patients aged <55 years by computer navigation (primary diagnosis OA, revision for loosening/lysis)</th>

Computer navigation	N revised	N total	1 yr	3 yrs	5 yrs	7 yrs	10 yrs	15 yrs
Computer navigated	71	5,661	0.2 (0.1, 0.4)	1.1 (0.8, 1.4)	1.7 (0.8, 1.4)	2.5 (1.9, 3.3)	3.1 (2.2, 3.3)	-
Non navigated	690	26,113	0.4 (0.4, 0.5)	1.5 (1.4, 1.7)	1.5 (1.4, 1.7)	2.9 (2.7, 3.2)	4.0 (3.7, 4.4)	6.9 (5.8, 8.4)
Total	761	31,774	-	_	_	-	-	_



Figure 8 Cumulative percent revision of primary total knee replacement in patients aged <55 years by computer navigation (primary diagnosis OA, revision for loosening/lysis).

compared to 5.1% for other femoral stems. However, there is not yet a difference in outcomes when a mini stem is used (*Figure 9*). This result means that mini stems can still be used in patients who meet the indications.

Modular femoral stems are widely used for some difficult cases especially in DDH patients because it enables the surgeons to have increased choice with femoral neck version, offset and leg length. This type of femoral stem is called femoral stems with exchangeable necks in the AOANJRR reports. There have been 9,745 procedures using femoral stems with exchangeable necks undertaken for OA. The 10-year revision rate for this type of stem is 9.3% compared to 4.9% for fixed neck stems, which is almost twice the revision rate compared to fixed neck stems

Femoral stem	Acetabular component	N revised	N total	THR	Fermoral	Acetabular	Other	5 yrs	10 yrs	15 yrs
Exeter	Vitalock*	54	1,076	6	10	22	16	2.3 (1.5, 3.4)	4.6 (3.4, 6.1)	6.3 (4.8, 8.3)
Mallory-head	Mallory-Head	141	2,812	13	12	45	71	3.0 (2.4, 3.7)	5.0 (4.1, 6.1)	9.8 (7.9, 12.2)
Omnifit	Secur-Fit*	74	716	7	20	17	30	6.2 (4.6, 8.2)	10.0 (7.9, 12.6)	12.4 (9.9, 15.5)
Omnifit	Trident (Shell)	121	3,497	12	28	20	61	3.1 (2.5, 3.7)	3.9 (3.2, 4.7)	5.5 (4.0, 7.4)
Secur-fit plus	Trident (Shell)	146	5,182	11	38	35	62	2.2 (1.8, 2.6)	3.2 (2.7, 3.8)	4.3 (3.4, 5.4)
Spectron EF	Reflection (Shell)	225	4,564	46	72	35	72	2.7 (2.2, 3.3)	5.7 (4.9, 6.6)	10.3 (8.6, 12.3)
Synergy	Reflection (Shell)	271	7,238	23	52	92	104	2.5 (2.2, 2.9)	3.9 (3.4, 4.4)	6.3 (5.1, 7.9)
Total	_	1,032	25,085	118	232	266	416	_	_	_

Table 12 Cumulative percent revision of primary total conventional hip replacement combinations with 15 year data (primary diagnosis OA)

Only combinations with over 350 procedures have been listed. *, it denotes prosthesis combinations that have not had any reported use in primary total conventional hip procedures in 2015.

Page 8 of 9

Table 13 Cumulative percent revision of primary total conventional hip replacement combinations with 10 year data (primary diagnosis OA)

Femoral component	Tibial component	N revised	N total	TKR	Fermoral	Tibial	Other	5 yrs	10 yrs	15 yrs
AGC	AGC	222	5,020	79	4	24	115	3.1 (2.6, 3.6)	4.8 (4.2, 5.6)	7.7 (6.3, 9.3)
Advantim	Advantim*	54	1,454	22	3	3	26	3.1 (2.3, 4.2)	4.7 (3.5, 6.2)	5.4 (3.9, 7.3)
Duracon	Duracon*	977	19,830	227	29	65	656	3.4 (3.2, 3.7)	4.9 (4.6, 5.3)	6.8 (6.3, 7.5)
Genesis II CR	Genesis II	678	19,727	133	46	42	457	3.4 (3.1, 3.7)	4.6 (4.2, 5.0)	5.7 (5.0, 6.5)
Genesis II CR	Profix Mobile*	89	1,209	33	9	7	40	5.3 (4.2, 6.8)	7.4 (5.9, 9.2)	10.6 (8.4, 13.4)
Kinemax plus	Kinemas Plus*	102	1,815	55	3	5	39	3.2 (2.4, 4.1)	4.6 (3.7, 5.7)	7.9 (6.4, 9.8)
LCS CR	LCS	540	8,290	215	23	83	219	4.4 (4.0, 4.9)	6.2 (5.7, 6.8)	7.9 (7.2, 8.7)
Natural Knee II	Natural Knee II	334	6,443	124	8	58	144	2.8 (2.4, 3.3)	5.5 (4.9, 6.2)	10.1 (8.6, 11.9)
Nexgen CR	Nexgen	308	10,726	94	12	30	172	2.0 (1.7, 2.3)	3.0 (2.7, 3.4)	4.5 (3.8, 5.4)
Nexgen LPS	Nexgen	266	6,416	62	17	30	157	3.2 (2.8, 3.7)	5.0 (4.4, 5.7)	5.8 (5.1, 6.7)
PFC sigma CR	PFC Sigma	532	21,660	111	41	45	335	2.4 (2.2, 2.6)	3.5 (3.1, 3.8)	5.0 (4.2, 5.9)
Profix	Profix*	252	5,370	52	13	18	169	3.7 (3.2, 2.6)	5.1 (4.5, 5.8)	5.4 (4.7, 6.2)
Scorpio CR	Series 7000	462	10,880	112	22	39	289	3.4 (3.1, 3.8)	5.2 (4.7, 5.7)	6.4 (5.7, 7.2)
Scorpio PS	Series 7000	285	4,659	92	7	58	128	4.7 (4.1, 5.4)	7.0 (6.2, 7.9)	11.5 (8.8, 14.8)
Total	_	5,101	123,499	1,411	237	507	2,946	-	-	

Only combinations with over 350 procedures have been listed. *, it denotes prosthesis combinations that have not had any reported use in primary total knee procedures in 2015.



Figure 9 Cumulative percent revision of primary total conventional hip replacement by stem type (primary diagnosis OA).

(*Table 14, Figure 10*). These results indicate that we should use these types of stems cautiously unless it is necessary.

We have analyzed the results that we find interesting, and the analysis and interpretations are based on our personal understanding and clinical experience. There are more details in the annual report, we strongly recommend all our readers to check the results that they find interesting and try to find the answers or references to their clinical questions. We are also happy to answer any questions or discuss variations in interpretation of the AOANJRR reports.

Acknowledgments

Funding: None.

Table 14	Cumulative perce	nt revision of primar	v total convention	onal hip replacem	ent by type of fem	oral neck (primar	v diagnosis OA
	1	1	-	1 1	~ ~ 1	U U	, ,

Femoral neck	N revised	N total	1 yr	3 yrs	5 yrs	7 yrs	10 yrs	15 yrs
Exchangeable	635	9,745	2.8 (2.5, 3.1)	4.6 (4.1, 5.0)	6.2 (5.7, 6.8)	7.9 (7.3, 8.6)	9.3 (8.5, 10.2)	-
Fixed	9,397	282,820	1.5 (1.4, 1.5)	2.3 (2.2, 2.4)	3.0 (2.9, 3.0)	3.7 (3.6, 3.8)	4.9 (4.8, 5.1)	7.8 (7.5, 8.2)
Total	10,032	292,565	_	_	-	_	_	-



Figure 10 Cumulative percent revision of primary total conventional hip replacement by type of femoral neck (primary diagnosis OA).

Footnote

Provenance and Peer Review: This article was a standard submission to the journal. The article has undergone external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi. org/10.21037/aoj.2017.02.01). The authors have no conflicts of interest to declare.

doi: 10.21037/aoj.2017.02.01

Cite this article as: Huang T, Wang W, George D, Mao X, Graves S. What can we learn from Australian Orthopaedic Association National Joint Replacement Registry 2016 annual report? Ann Joint 2017;2:11. *Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

- Huang T, Wang W, George D, et al. What can we learn from AOANJRR 2014 annual report? Ann Transl Med 2015;3:131.
- Australian Orthopaedic Association National Joint Replacement Registry 2016. Hip Knee and Shoulder Arthroplasty Annual Report 2016. Available from: https://aoanjrr.sahmri.com/documents/10180/275066/ Hip%2C%20Knee%20%26%20Shoulder%20 Arthroplasty